- Home
- PAVM vs PRPO Comparison
PAVM vs PRPO Comparison
Compare PAVM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- PRPO
- Stock Information
- Founded
- PAVM 2014
- PRPO N/A
- Country
- PAVM United States
- PRPO United States
- Employees
- PAVM N/A
- PRPO N/A
- Industry
- PAVM Medical/Dental Instruments
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- PAVM Health Care
- PRPO Industrials
- Exchange
- PAVM Nasdaq
- PRPO Nasdaq
- Market Cap
- PAVM 8.0M
- PRPO 9.9M
- IPO Year
- PAVM 2016
- PRPO N/A
- Fundamental
- Price
- PAVM $0.79
- PRPO $7.22
- Analyst Decision
- PAVM Strong Buy
- PRPO
- Analyst Count
- PAVM 1
- PRPO 0
- Target Price
- PAVM $19.00
- PRPO N/A
- AVG Volume (30 Days)
- PAVM 195.9K
- PRPO 5.9K
- Earning Date
- PAVM 03-25-2025
- PRPO 03-28-2025
- Dividend Yield
- PAVM N/A
- PRPO N/A
- EPS Growth
- PAVM N/A
- PRPO N/A
- EPS
- PAVM 0.53
- PRPO N/A
- Revenue
- PAVM $4,034,000.00
- PRPO $17,411,000.00
- Revenue This Year
- PAVM $52.90
- PRPO $75.18
- Revenue Next Year
- PAVM $248.84
- PRPO N/A
- P/E Ratio
- PAVM $1.50
- PRPO N/A
- Revenue Growth
- PAVM 166.27
- PRPO 31.31
- 52 Week Low
- PAVM $0.57
- PRPO $4.31
- 52 Week High
- PAVM $3.50
- PRPO $7.55
- Technical
- Relative Strength Index (RSI)
- PAVM 64.34
- PRPO 62.56
- Support Level
- PAVM $0.62
- PRPO $7.02
- Resistance Level
- PAVM $0.79
- PRPO $7.55
- Average True Range (ATR)
- PAVM 0.07
- PRPO 0.25
- MACD
- PAVM 0.02
- PRPO 0.05
- Stochastic Oscillator
- PAVM 95.00
- PRPO 73.78
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.